Target Price | $507.67 |
Price | $440.87 |
Potential | 15.15% |
Number of Estimates | 24 |
24 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $507.67. This is 15.15% higher than the current stock price. The highest price target is $621.00 40.86% , the lowest is $330.00 25.15% . | |
A rating was issued by 34 analysts: 18 Analysts recommend Vertex Pharmaceuticals to buy, 14 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 15.15% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
27 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $11.9b . This is 7.50% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.2b 10.33% , the lowest is $11.8b 5.89% .
This results in the following potential growth metrics:
2024 | $11.0b | 11.66% |
---|---|---|
2025 | $11.9b | 8.27% |
2026 | $13.2b | 10.84% |
2027 | $14.5b | 9.38% |
2028 | $15.8b | 8.94% |
2029 | $17.5b | 11.00% |
7 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.5b . This is 25.26% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.0b 36.70% , the lowest is $4.5b 2.11% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.6b | 1.37% |
---|---|---|
2025 | $5.5b | 20.03% |
2026 | $6.8b | 23.43% |
2027 | $7.4b | 9.13% |
2028 | $8.1b | 9.21% |
2029 | $9.2b | 13.79% |
2024 | 41.77% | 9.21% |
---|---|---|
2025 | 46.30% | 10.85% |
2026 | 51.56% | 11.36% |
2027 | 51.45% | 0.21% |
2028 | 51.57% | 0.23% |
2029 | 52.87% | 2.52% |
15 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $3.9b . This is 491.65% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.1b 514.64% , the lowest is $3.7b 473.67% .
This results in the following potential growth metrics and future Net Margins:
2024 | $-536m | 114.80% |
---|---|---|
2025 | $3.9b | 823.11% |
2026 | $4.6b | 19.86% |
2027 | $5.3b | 15.19% |
2028 | $6.4b | 20.61% |
2029 | $7.0b | 8.71% |
2024 | -4.86% | 113.25% |
---|---|---|
2025 | 32.46% | 767.87% |
2026 | 35.10% | 8.13% |
2027 | 36.97% | 5.33% |
2028 | 40.93% | 10.71% |
2029 | 40.08% | 2.08% |
15 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $15.07 . This is 495.54% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.96 518.90% , the lowest is $14.38 477.43% .
This results in the following potential growth metrics and future valuations:
2024 | $-2.08 | 114.97% |
---|---|---|
2025 | $15.07 | 824.52% |
2026 | $18.06 | 19.84% |
2027 | $20.81 | 15.23% |
2028 | $25.10 | 20.62% |
2029 | $27.28 | 8.69% |
Current | -115.71 | 470.44% |
---|---|---|
2025 | 29.25 | 125.28% |
2026 | 24.40 | 16.58% |
2027 | 21.19 | 13.16% |
2028 | 17.57 | 17.08% |
2029 | 16.16 | 8.03% |
Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 8.98 and an P/S ratio of 9.49 .
This results in the following potential growth metrics and future valuations:
Current | 9.65 | 13.99% |
---|---|---|
2025 | 8.98 | 6.96% |
2026 | 8.10 | 9.78% |
2027 | 7.41 | 8.57% |
2028 | 6.80 | 8.21% |
2029 | 6.12 | 9.91% |
Current | 10.20 | 16.26% |
---|---|---|
2025 | 9.49 | 6.97% |
2026 | 8.56 | 9.78% |
2027 | 7.83 | 8.57% |
2028 | 7.18 | 8.21% |
2029 | 6.47 | 9.91% |
Vertex Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jun 20 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Jun 17 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | May 06 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | May 06 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | May 06 2025 |
Leerink Partners |
Outperform
➜
Market Perform
|
Downgrade | May 06 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | May 06 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jun 20 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Jun 17 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
May 06 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
May 06 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
May 06 2025 |
Downgrade
Leerink Partners:
Outperform
➜
Market Perform
|
May 06 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
May 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.